超声引导衰减参数技术定量评估肝脏脂肪变性的价值

doi:10.3969/j.issn.1004-583X.2025.02.011

摘要/Abstract

摘要：

目的探讨超声影像引导衰减参数(ultrasound guided attenuation parameter, UGAP)定量检测肝脏脂肪变性的可行性。方法选取2024年2-6月期间于大连大学附属中山医院行肝脏超声检查的患者102例,同时行UGAP检查和收集血脂、腹部CT检查结果,比较分析UGAP检测所得的衰减参数(attenuation coefficient,AC)与甘油三酯(triglycerides, TG)、胆固醇(thermoelectric cell, TC)以及体重指数(body mass index, BMI)的相关性。结果有74例影像学确诊为脂肪肝,其中轻度30例,中度18例,重度26例,另有28例影像正常患者作为健康对照组,脂肪肝组与对照组的BMI、TG、TC水平及肝脏CT值、肝脾CT比值差异存在统计学意义,年龄差异无统计学意义。健康对照组与脂肪肝组的AC值差异有统计学意义,其中轻度、中度、中度脂肪肝的各亚组间AC值差异也具有统计学意义。结论 UGAP在无创、定量评估肝脏脂肪变性中具有一定的临床应用价值。

关键词: 脂肪肝, 超声引导衰减参数, 定量评估

Abstract:

Objective To explore the feasibility of ultrasound guided attenuation parameter (UGAP) in the quantitative detection of hepatic steatosis. Methods A total of 102 patients who underwent liver ultrasound examination in Affiliated Zhongshan Hospital of Dalian University from February 2024 to June 2024 were selected. UGAP, blood lipids and abdominal computed tomography (CT) findings were collected. The correlation of attenuation coefficient (AC) obtained by UGAP with triglycerides (TG), total cholesterol (TC) and body mass index (BMI) was analyzed. Results A total of 74 patients diagnosed with fatty liver disease were included in the study, including 30 mild cases, 18 moderate cases, and 26 severe cases, and 28 healthy subjects with normal imaging findings were selected as the control group. There were significant differences in the BMI, TG, TC, liver CT value, and liver CT/spleen CT ratio between the fatty liver group and the control group, but age was comparable. There was a significant difference in AC value between groups, so as that among the mild, moderate and severe subgroups. Conclusion UGAP has certain clinical application value in the non-invasive and quantitative evaluation of hepatic steatosis.

Key words: fatty liver, ultrasound guided attenuation parameter, quantitative assessment

中图分类号:

R575.5

孙雅, 杨爽. 超声引导衰减参数技术定量评估肝脏脂肪变性的价值[J]. 临床荟萃, 2025, 40(2): 158-161.

Sun Ya, Yang Shuang. Value of ultrasound-guided attenuation parameter in the quantitative assessment of hepatic steatosis[J]. Clinical Focus, 2025, 40(2): 158-161.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2025.02.011

https://lchc.magtechjournal.com/CN/Y2025/V40/I2/158

图/表 3

参考文献 21

[1]	Lazarus J, Mark H, Anstee Q, et al. NAFLD consensus consortium. advancing the global public health agenda for NAFLD: A consensus statement[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(1):60-78.
[2]	Rockey D, Caldwell S, Goodman Z, et al. American Association for the Study of Liver Diseases. Liver biopsy[J]. Hepatology, 2009, 49:1017-1044. doi: 10.1002/hep.22742 pmid: 19243014
[3]	中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 实用肝脏病杂志, 2007, 10(1):1-3.
[4]	许耀珑, 赵佳欣, 杨立刚. 非酒精性脂肪性肝病流行现状及危险因素研究进展[J]. 中国全科医学, 2024, 27(30):3825-3834. doi: 10.12114/j.issn.1007-9572.2023.0893
[5]	Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up[J]. Hepatology, 2015, 61(5):1547-1554. doi: 10.1002/hep.27368 pmid: 25125077
[6]	Fujiwara Y, Kuroda H, Abe T, et al. The B-mode image-guided ultrasound attenuation parameter accurately detects hepatic steatosis in chronic liver disease[J]. Ultrasound Med Biol, 2018, 44(11):2223-2232. doi: S0301-5629(18)30272-2 pmid: 30077415
[7]	Bende F, Sporea I, Sirli R, et al. Ultrasound-guided attenuation parameter (UGAP) for the quantification of liver steatosis using the controlled attenuation parameter (CAP) as the reference method[J]. Med Ultrason, 2021, 23(1): 7-14. doi: 10.11152/mu-2688 pmid: 33220028
[8]	柯坚. 人体组织超声衰减成像新技术[J]. 中国超声医学杂志, 2000, (10):4-8.
[9]	Tada T, Kumada T, Toyoda H, et al. Utility of attenuation coefficient measurement using an ultrasound-guided attenuation parameter for evaluation of hepatic steatosis: Comparison with MRI-determined proton density fat fraction[J]. AJR Am J Roentgenol, 2019, 212(2):332-341.
[10]	Zhao Y, Jia M, Zhang C, et al. Reproducibility of ultrasound-guided attenuation parameter (UGAP) to the noninvasive evaluation of hepatic steatosis[J]. Sci Rep, 2022, 12(1):2876. doi: 10.1038/s41598-022-06879-0 pmid: 35190618
[11]	于晶晶. 肝功能和血脂及血糖水平联合检测在非酒精性脂肪肝患者病情评估中的应用价值[J]. 临床医药实践, 2020, 29(6):437-439.
[12]	中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5):947-957.
[13]	张姝嫔, 程成, 祝怡婕, 等. 超声衰减成像定量诊断非酒精性脂肪肝的应用价值初探讨[J]. 中国超声医学杂志, 2021, 37(1):66-69.
[14]	Iwashita H, Shakado S, Yoshimaru N, et al. Clinical utility of ultrasound-guided attenuation parameter for the detection and quantification of hepatic steatosis in patients with fatty liver diagnosed by computed tomography[J]. Ultrasound Med Biol, 2022, 48(7):1282-1289. doi: 10.1016/j.ultrasmedbio.2022.02.023 pmid: 35397929
[15]	Kodama Y, Ng CS, Wu TT, et al. Comparison of CT methods for determining the fat content of the liver[J]. AJR Am J Roentgenol, 2007, 188(5):1307-1312.
[16]	惠斌. CT在脂肪肝定量诊断中的应用价值分析[J]. 影像研究与医学应用, 2017, 1(11):131-132.
[17]	European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015, 63(1):237-264. doi: 10.1016/j.jhep.2015.04.006 pmid: 25911335
[18]	Kumada T, Ogawa S, Goto T, et al. Intra-individual comparisons of the ultrasound-guided attenuation parameter and the magnetic resonance imaging-based proton density fat fraction using bias and precision statistics[J]. Ultrasound Med Biol, 2022, 48(8):1537-1546.
[19]	Kuroda H, Fujiwara Y, Abe T, et al. Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis[J]. PLoS One, 2021, 16(4):e0249493.
[20]	Kumada T, Toyoda H, Yasuda S, et al. Liver stiffness measurements by 2D shear-wave elastography: Effect of steatosis on fibrosis evaluation[J]. AJR Am J Roentgenol, 2022, 219(4):604-612.
[21]	Kang K, Lee S, Jun D, et al. Diagnostic performance of a novel ultrasound-based quantitative method to assess liver steatosis in histologically identified nonalcoholic fatty liver disease[J]. Med Ultrason, 2023, 25(1):7-13. doi: 10.11152/mu-3815 pmid: 36780603

组别	例数	BMI(kg/m²)	TC(mmol/L)	TG(mmol/L)	肝脏CT值(HU)	肝脾CT比值
健康对照组	28	21.07±2.59	4.16±1.00	1.21±0.76	60.46±5.05	1.28±0.10
脂肪肝组	74	26.30±3.30	4.88±1.33	2.12±1.40	47.68±10.08	0.99±0.20
t值		1.944	2.312	2.765	16.107	9.206
P值		<0.01	<0.01	<0.01	<0.01	<0.01

组别	例数	BMI(kg/m²)	TC(mmol/L)	TG(mmol/L)	肝脏CT值(HU)	肝脾CT比值
健康对照组	28	21.07±2.59	4.16±1.00	1.21±0.76	60.46±5.05	1.28±0.10
脂肪肝组	74	26.30±3.30	4.88±1.33	2.12±1.40	47.68±10.08	0.99±0.20
t值		1.944	2.312	2.765	16.107	9.206
P值		<0.01	<0.01	<0.01	<0.01	<0.01

组别	例数	AC值(dB·cm^-1·MHz^-1)
健康对照组	28	0.50±0.06
脂肪肝组	74	0.69±0.08
轻度	30	0.61±0.04
中度	18	0.70±0.04
重度	26	0.78±0.03
F值		206.062
P值		<0.01

组别	例数	AC值(dB·cm^-1·MHz^-1)
健康对照组	28	0.50±0.06
脂肪肝组	74	0.69±0.08
轻度	30	0.61±0.04
中度	18	0.70±0.04
重度	26	0.78±0.03
F值		206.062
P值		<0.01